авторы Неоновой:
AcompliaCheapMD [acomplia3445@mymail-in.net]
Статус: 
(писатель)
The drug Acomplia ® (Rimonabant) is allowed for sale in the EU First in-class CB1 blocker is permitted for use in patients with obesity or overweight in the presence of associated risk factors, such as diabetes mellitus type 2, or dyslipidemia. Paris, France, June 21, 2006 - Sanofi-aventis announced that the European Commission issued a permit to sell the drug ACOMPLIA ® (rimonabant, 20 mg / day) in all 25 European member states. The drug ACOMPLIA ®, an open and developed by sanofi-aventis, is the first in a new class of drugs called CB1 blockers. ACOMPLIA ® is recommended in addition to diet and exercise to treat obesity (BMI ? 30 kg/m2) or overweight (BMI> 27 kg/m2) with associated risk factors such as diabetes mellitus type 2, or dyslipidemia. Permission to sell the drug is issued after considering a large number of data on efficacy and safety, including clinical trial data RIO, which was attended by over 6000 patients worldwide, 4500 of these patients were examined during the biennium. RIO program results have shown that taking the drug ACOMPLIA ® tablets 20 mg daily significantly reduces body weight and waist circumference, and levels of HbA1c and triglycerides and increases HDL cholesterol. In conclusion, the European Commission said that 50% of the observed improvement in levels of HbA1c, HDL cholesterol and triglyceride levels higher than the result expected on the basis of only reduce vesa.1
посмотреть все комментарии на работы автора
группы текстов:
